| Type | Private |
|---|---|
| Industry | Pharmaceutical Industry |
| Founded | 1983 |
| Headquarters | Lachen, Switzerland |
| Number of locations | 38 |
| Products | octaplas, octagam,octagam10%, octanate, octanyne, octaplex, octavi SD Optimum, octalbin, uniplas, rhesonativ, aunativ, gammonativ, atenativ, gammanorm, nanotiv, octonativ, octanine F, wilate See complete products listing. |
| Revenue | Euro 718 million (2010)[1] |
| Employees | 4'238 (2010) |
| Website | www.octapharma.com |
Octapharma AG is the largest privately owned plasma product manufacturer in the world. It is headquartered in Lachen, Switzerland.
Octapharma’s core business is the development, production and sale of high quality human proteins derived from blood plasma or recombinant technologies. The privately owned company currently employs over 4,000 employees worldwide with biopharmaceutical sales and expertise in more than 80 countries.[2]
Contents |
Octapharma’s R&D departments are located in Vienna (Austria), Frankfurt, Berlin, Munich (all in Germany) as well as in Stockholm (Sweden). The main focus is the development and enhancement of proteins for use in the three therapeutic areas of Immunotherapy, Coagulation and Intensive Care and Emergency Medicine.[3]
Current R&D Projects (August 2010)
The company's therapies are used in the treatment of many different diseases in the areas of Coagulation (Hemophilia A, B and von Willebrand), Immunotherapy (autoimmune diseases, antibody deficiency, Rhesusprophylaxis) and Intensive Care and Emergency Medicine (DIC, blood clotting disorder, Thrombotic-thromozytopenic purpura, TRALI)[4]
Founded in 1983, Octapharma is a privately owned company with its headquarter in Lachen, Switzerland. The over 4,000 employees work in 28 subsidiaries worldwide. In addition Octapharma currently operates five state-of-the art manufacturing facilities in Vienna (Austria), Stockholm (Sweden), Lingolsheim (France), Springe (Germany) and Mexico City (Mexico).[5]
In recognition of the changed market conditions for plasma, Octapharma began acquiring plasma collection centers in the United States,[6] Germany and Czech Republic in 2005. It is planned to source approximately 50% of the plasma needed for production of the Octapharma products from Octapharma-owned plasma centers by 2012.